This is a routine conference update with no new data — no immediate trading catalyst. Monitor for FDA's independent evaluation of the sunRIZE dataset, which could determine the regulatory path for ersodetug. The failed Phase 3 remains the key overhang; any positive FDA feedback would be a significant catalyst.
Price Chart
Executive Summary
Rezolute announced four presentations at the ENDO 2026 conference, including an oral presentation of previously reported Phase 3 sunRIZE results for ersodetug in congenital hyperinsulinism. The Phase 3 study failed to meet its primary or key secondary endpoints in December 2025, and the FDA has requested comprehensive data for independent evaluation. This press release is a routine scientific conference update with no new clinical data or material financial information.
Key Facts
- Rezolute will present four presentations at ENDO 2026 (June 13-16, 2026) in Chicago.
- One oral presentation will highlight previously reported Phase 3 sunRIZE results for ersodetug in congenital hyperinsulinism.
- The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints (announced December 2025).
- FDA encouraged Rezolute to submit comprehensive analysis datasets for independent evaluation.
- Three poster presentations cover natural history of congenital HI, compassionate use of ersodetug in tumor HI, and systematic review of outcomes.
- No new clinical data, financial results, or regulatory milestones are reported in this press release.
Financial Impact
No financial figures disclosed; the press release is a scientific conference update with no material financial impact.
Risk Factors
- Phase 3 sunRIZE study failed primary and key secondary endpoints — regulatory path for ersodetug is uncertain.
- FDA independent evaluation could result in a complete response letter or additional trial requirements.
- No revenue or near-term commercialization timeline — stock is binary on regulatory outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | DEF 14A | $3.86 | awaiting T+20 | — | $4.11 (+6.48%) |
Oct 14, 2026 13d ago | 8-K | $3.90 | awaiting T+20 | — | $4.11 (+5.38%) |
Oct 5, 2026 22d ago | 8-K | $4.33 | awaiting T+20 | — | $4.11 (−5.08%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $4.11 (−19.25%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $4.11 (+6.48%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $4.11 (−8.87%) |
Jun 2, 2026 21w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $4.11 (+2.75%) |
May 12, 2026 24w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $4.11 (+23.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers